Granisetron clinical trials
Granisetron is named as an intervention in 2 current clinical trials in our Turkey and Egypt registers. 1 is recruiting patients now. The most common phase is Observational. The sponsor with the most trials is Kayseri City Hospital (1). The most-studied condition is Hypotension.
Where Granisetron is approved
All regulators →Of the three regulators tracked here, the first to approve Granisetron was the US, on 29 Dec 1993. It is approved in 3 of the 3 regulators tracked here.
From the regulators' own registers: FDA Drugs@FDA, the EMA medicines list and Health Canada's Notice of Compliance database. Dates are the first listed approval of a product containing only this substance; combination products and nationally authorised EU medicines are not counted.
What health systems spend on Granisetron
All medicines →From NHSBSA Prescription Cost Analysis (Open Government Licence v3.0) and CMS State Drug Utilization Data. Both are gross amounts: neither system publishes its discounts or rebates per drug. Products combining several substances are not counted here.
How Granisetron works
All drug targets →- Serotonin 3a (5-HT3a) receptor antagonist AntagonistTarget: HTR3A 5-hydroxytryptamine receptor 3A✓ In ChEMBL and the Guide to Pharmacology
- Acute kidney injuryPhase 3
- Cesarean sectionPhase 3
- Post operative nausea and vomitingPhase 3
- PruritusPhase 2
- SepsisPhase 2
- Septic shockPhase 2
- PainPhase 1
Mechanisms and diseases from ChEMBL via the Open Targets Platform (release 26.09), ChEMBL record CHEMBL289469, CC BY-SA 3.0. Targets checked against the IUPHAR/BPS Guide to PHARMACOLOGY (2026.3.1), ligand 2300, CC BY-SA 4.0. Trial phases are not approvals: approved uses are shown from the regulators' own records where we hold them.
Patient leaflets for Granisetron
The package leaflet is the official guide for patients that comes with every medicine. These links go to the regulators that publish it.
- IEIreland: 5 products on the HPRA listEach product record links to the HPRA, which publishes the leaflet and SmPC.
- EUEuropean Union: SancusoEMA product information: package leaflet and summary of product characteristics in every EU language.
- UKUnited Kingdom: Search MHRA ProductsPatient information leaflets and SmPCs for UK-licensed products.
- USUnited States: Search DailyMedFDA-approved labels, including patient and medication guides.
Leaflets differ between brands and countries; always read the one that comes with your own medicine. This is regulatory information, not medical advice.
Reference identifiers for Granisetron
- ATC code
- A04AA02
- ChEMBL
- CHEMBL289469
- DrugBank
- DB00889
- PubChem CID
- 3510
- CAS number
- 109889-09-0
- FDA UNII
- WZG3J2MCOL
- Wikidata
- Q596708
- Wikipedia
- Granisetron
Codes that identify this medicine in other databases, from Wikidata (CC0), matched by its ChEMBL ID. The ATC code is the WHO classification of what the medicine is used for.
Trials by status
Trials by phase
Clinical trials of Granisetron
2 trials| Study | Phase | Status | Lead sponsor | Registers |
|---|---|---|---|---|
|
Granisetron Use, Blood Pressure, and Nausea and Vomiting During Cesarean Delivery Under Spinal Anesthesia
NCT07861737 · ClinicalTrials.gov ↗ · Hypotension, Nausea, Vomiting
|
Observational | Recruiting | Kayseri City Hospital | Turkey |
|
Occlusal Splint Combined With Granisetron Injection for Management of Myofascial Pain Related to Temporomandibular Disorders
NCT07401745 · ClinicalTrials.gov ↗ · TMD, TMD/Orofacial Pain, Temporomandibular Disorder (TMD)
|
Phase 4 | Active, closed | Mansoura University | Egypt |
Registers list studies that are recruiting, about to open, active but closed to enrolment, or enrolling by invitation. The UK and USA registers cover industry-sponsored studies only. Trial titles and statuses are copied from the registry as published.
Granisetron across our data
Ireland · EU · USThe same active substance in our other registers, matched by its exact name. Each entry links to the register record it comes from.
Licensed in Ireland (HPRA)
5 single-substance products containing Granisetron on the HPRA medicines list.
- Kytril 1 mg/1 ml solution for injectionAtnahs Pharma Netherlands B.V. · PA22657/003/001 · Marketed
- Kytril 1mg film-coated tabletsAtnahs Pharma Netherlands B.V. · PA22657/003/003 · Marketed
- Kytril 2mg film-coated tabletsAtnahs Pharma Netherlands B.V. · PA22657/003/004 · Marketed
- Kytril 3 mg/3 ml solution for injectionAtnahs Pharma Netherlands B.V. · PA22657/003/002 · Marketed
- SANCUSO 3.1 mg/24 hours transdermal patchGrünenthal GmbH · EU/1/12/766/001
Supply shortages
- Granisetron Kabi 1 mg/ml Konzentrat zur Herstellung einer Injektionslösung/InfusionslösungGermany (BfArM) · Other reason · 30 Oct 2026 to 14 Dec 2026
Conditions studied with Granisetron
7 conditionsSponsors
lead sponsor per trial| Lead sponsor | Trials |
|---|---|
| Kayseri City Hospital | 1 |
| Mansoura University | 1 |
By country register
| Register | Trials | Recruiting |
|---|---|---|
| Clinical trials in Turkey | 1 | 1 |
| Clinical trials in Egypt | 1 | 0 |
A trial with sites in more than one country appears in each of those registers.
Related compounds
Questions about Granisetron trials
How many clinical trials are testing Granisetron?
2 current trials in our Turkey and Egypt registers name Granisetron as a drug or biological intervention, as of the registry sync on 22 November 2026. Completed and withdrawn studies are not counted.
Are Granisetron trials recruiting patients?
Yes. 1 of the 2 trials is recruiting: 1 with sites in Turkey. Eligibility and site contacts are on each trial's record. Only the study team can confirm whether a patient is eligible.
Who sponsors Granisetron clinical trials?
Kayseri City Hospital (1) and Mansoura University (1). The number in brackets is how many trials each organisation leads.
Is Granisetron licensed in Ireland?
Yes. The HPRA medicines list includes 5 single-substance products containing Granisetron, for example Kytril 1 mg/1 ml solution for injection (Atnahs Pharma Netherlands B.V.). A licence does not mean a product is currently marketed or reimbursed; see each product's record.
Is there a Granisetron shortage?
The registers we track list 1 entry for Granisetron: 1 German notice. Shortages are product- and country-specific; check with a pharmacist.
Where does this information come from?
Every trial, status, phase and sponsor on this page is copied from public ClinicalTrials.gov records by a daily sync. Nothing here describes how Granisetron works or whether it is effective, and it is not medical advice.
How this page is built
Everything on this page is copied from public ClinicalTrials.gov registry records — it is not written from memory, and nothing here describes how Granisetron works or whether it is effective. Each trial links to its own record so you can check it yourself.
- ClinicalTrials.gov (U.S. National Library of Medicine) ↗ Trial IDs, titles, intervention names and synonyms, phase, overall status, lead sponsor and conditions for every trial on this page
This page is built automatically: a daily sync job reads the registry records behind our country trial registers, collects every trial that lists Granisetron (or a registered synonym) as a drug or biological intervention, and tabulates the registry fields directly. Placebos and generic comparators are excluded. There is no AI drafting and no per-compound editorial pass, and the page has not been clinically reviewed. The “last verified” date above is the timestamp of that sync, not a review date. Our general editorial approach is described in our editorial standards and corrections policy. The ClinicalTrials.gov data on this page was last retrieved on 22 Nov 2026. How every register is built: methodology · fixes we have made: corrections log.